ABC | Volume 113, Nº1, Julho 2019

Posicionamento Posicionamento sobre Antiagregantes Plaquetários e Anticoagulantes em Cardiologia – 2019 Arq Bras Cardiol. 2019; 113(1):111-134 89. Singer DE, Hughes RA, Gress DR, SheehanMA, Oertel LB, Maraventano SW, et al; Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323(22):1505-11. 90. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991;84(2):527-39. 91. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343(8899):687-91. 92. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo- controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1(8631):175-9. 93. EzekowitzMD,BridgersSL,JamesKE,CarlinerNH,CollingCL,GornickCC, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention inNonrheumatic Atrial Fibrillation Investigators. N Engl J Med. 1992;327(20):1406-12. Erratum in: N Engl J Med 1993;328(2):148. 94. ConnollySJ,LaupacisA,GentM,RobertsRS,Cairns JA, JoynerC.Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18(2):349-55. 95. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154(13):1449-57. Erratum in: Arch Intern Med. 1994;154(19):2254. 96. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-67. 97. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288(19):2441-8. 98. Cooper NJ, Sutton AJ, Lu G, Khunti K. Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med. 2006;166(12):1269-75. 99. Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, et al; ROCKET AF Steering Committee & Investigators. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013;61(19):1998-2006. 100. Pallisgaard JL, Lindhardt TB, HansenML, Schjerning AM, Olesen JB, Staerk L, et al. Cardioversion and risk of adverse events with dabigatran versus warfarin: a nationwide cohort study. PLoSOne. 2015;10(10):e0141377. 101. Nuotio I, Hartikainen JE, Gronberg T, Biancari F, Airaksinen KE. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA. 2014;312(6):647-9. 102. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, et al; Assessment of Cardioversion Using Transesophageal Echocardiography Investigators.Useoftransesophagealechocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344(19):1411-20. 103. Bartel T, Erbel R; Acute Trial Investigators. Transoesophageal echocardiography for immediate and safe cardioversion in patients with atrial fibrillation. Eur Heart J. 2001;22(22):2041-4. 104. Gallagher MM, Hennessy BJ, Edvardsson N, Hart CM, ShannonMS, Obel OA, et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol. 2002;40(5):926-33. 105. Weigner MJ, Caulfield TA, Danias PG, SilvermanDI, ManningWJ. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med. 1997;126(8):615-20. 106. Kim M, Trohman R, Eagle K. Low molecular weight heparin in atrial fibrillation management: facts, fiction, future. Card Electrophysiol Rev. 2003;7(4):397-400. 107. Serrano Junior CV, Fenelon G, Soeiro AM, Nicolau JC, Piegas LS, Montenegro ST, et al. Sociedade Brasileira de Cardiologia. Diretrizes Brasileiras de antiagregantes plaquetários e anticoagulantes em cardiologia. Arq Bras Cardiol. 2013;101(3 Supl.3):1-93. 108. Hara H, Virmani R, Ladich E, Mackey-Bojack S, Titus J, Reisman M, et al. Patent foramen ovale: current pathology, pathophysiology, and clinical status. J Am Coll Cardiol. 2005;46(9):1768-76. 109. Wu LA, Malouf JF, Dearani JA, Hagler DJ, Reeder GS, Petty GW, et al. Patent foramen ovale in cryptogenic stroke: current understanding and management options. Arch Intern Med. 2004;164(9):950-6. 110. Kerut EK, Norfleet WT, Plotnick GD, Giles TD. Patent foramen ovale: a review of associated conditions and the impact of physiological size. J Am Coll Cardiol. 2001;38(3):613-23. 111. Meissner I, Khandheria BK, Heit JA, Petty GW, Sheps SG, Schwartz GL, et al. Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. J Am Coll Cardiol. 2006;47(2):440-5. 112. Di Tullio MR. Patent foramen ovale: echocardiographic detection and clinical relevance in stroke. J Am Soc Echocardiogr. 2010;23(2):144-55. 113. Penther P. [Patent foramen ovale: an anatomical study. Apropos of 500 consecutive autopsies]. Arch Mal Coeur Vaiss. 1994;87(1):15-21. 114. Schroeckenstein RF, Wasenda GJ, Edwards JE. Valvular competent patent foramen ovale in adults. Minn Med. 1972;55(1):11-3. 115. Hagen PT, ScholzDG, EdwardsWD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59(1):17-20. 116. Rigatelli G, Ronco F. Patent foramen ovale: a comprehensive review for pulmonologists. Curr Opin PulmMed. 2010;16(5):442-7. 117. Billinger M, Zbinden R, Mordasini R, Windecker S, Schwerzmann M, Meier B, et al. Patent foramen ovale closure in recreational divers: effect on decompression illness and ischaemic brain lesions during long-term follow-up. Heart. 2011;97(23):1932-7. 118. TortiSR,BillingerM,SchwerzmannM,VogelR,ZbindenR,WindeckerS,et al.Riskofdecompressionillnessamong230diversinrelationtothepresence and size of patent foramen ovale. Eur Heart J. 2004;25(12):1014-20. 119. Wohrle J, Kochs M, Hombach V, Merkle N. Prevalence of myocardial scar in patients with cryptogenic cerebral ischemic events and patent foramen ovale. JACC Cardiovasc Imaging. 2010;3(8):833-9. 120. Neisius U, Northridge DB, Cruden NL, Denvir MA. Myocardial infarction associated with patent foramen ovale and paradoxical embolism: case series. Int J Cardiol. 2015 Feb 1;180:34-7. 121. Lau EM, Yee BJ, Grunstein RR, Celermajer DS. Patent foramen ovale and obstructive sleep apnea: a new association? Sleep Med Rev. 2010;14(6):391-5. 122. Sevgi EB, Erdener SE, Demirci M, Topcuoglu MA, Dalkara T. Paradoxical air microembolism induces cerebral bioelectrical abnormalities and occasionally headache in patent foramen ovale patients with migraine. J AmHeart Assoc. 2012;1(6):e001735. 123. Rundek T, ElkindMS, Di TullioMR, Carrera E, Jin Z, Sacco RL, et al. Patent foramen ovale and migraine: a cross-sectional study from the Northern ManhattanStudy (NOMAS).Circulation.2008;118(14):1419-24.Erratum in: Circulation. 2008;118(18):e682. 124. Lip PZ, Lip GY. Patent foramen ovale and migraine attacks: a systematic review. Am J Med. 2014;127(5):411-20. 125. Dowson A, Mullen MJ, Peatfield R, Muir K, Khan AA, Wells C, et al. Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation. 2008;117(11):1397-404. Erratum in: Circulation. 2009;120(9):e71-2. 126. Cohnheim JF. Vorlesungen Uber Allgemenie Pathologie. 2nd ed. Berlin: August Hirschwald; 1987. 127. Rundek T. PFO in stroke: a direct association or coincidence? Eur J Neurol. 2008:15(9):887-8. 133